| Name | Title | Contact Details |
|---|
Evident.io is the leader in cloud infrastructure security for Amazon Web Services (AWS). The Evident Security Platform (ESP) is a cloud-native Security-as-a-Service solution that automates key cloud security processes and enables consistent enforcement of policy requirements across an organization`s entire AWS cloud. ESP was designed specifically to help modern IT and DevOps teams automate and maintain security within the AWS shared responsibility model. ESP combines automated detection of vulnerabilities and security mis-configurations with guided remediation, audit capabilities, and compliance requirements. It provides a continuous global view of security risk, with the actionable intelligence needed to rapidly remediate and secure an organization`s entire AWS Infrastructure. Evident.io is a privately held company based in Dublin, CA and backed by Bain Capital Ventures, Venrock and True Ventures.
Omicron Teletechnologies Inc. is a Pointe-Claire, QC-based company in the Computers and Electronics sector.
Netrox is a Miami, FL-based company in the Computers and Electronics sector.
IdentifySensors is a leading developer of digital diagnostic technologies on graphene-based biosensors. The company is principally focused on developing real-time pathogen detection capabilities for direct diagnosis and remote monitoring. The company`s technology has expanded into multiple industries and applications, such as pathogen diagnostics and testing for food contamination. Check4® by IdentifySensors Biologics® is a next-generation digital diagnostic platform intended to detect multiple pathogens within 5 minutes at the molecular gene level. The platform is intended to eliminates the need for enzymatic amplification and reagents. Graphene sensor technology has moved diagnostics beyond chemical testing into a rapid digital platform intended to be as accurate as a PCR test but significantly more sensitive and cost effective. Printed graphene sensors isolate targeted viruses and bacteria from saliva and other bodily fluids within a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for over-the-counter and point-of-care use. With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. The Check4® testing platform comes is two main parts: 1) A reader, which connects to a user`s cell phone or to a clinical database; and 2) Single-use test cartridges, which can contain multiple graphene sensors to detect multiple infections. The reader, which can be reused thousands of times, serves as the base of the platform, accepting any number of test cartridges. Disposable test cartridges, which require the reader to work, will be sold separately.
At Contentserv, we enable retailers and brands to develop the groundbreaking product experiences of the future by fully exploiting the potential offered by advanced technologies. Our vision is to make the daily lives of marketers and product teams easier by providing them with an advanced, complete, business-focused platform emphasizing time to value. We are driven by the desire to keep our customers one step ahead of the competition. By combining Product Information Management (PIM), Master Data Management (MDM), and Marketing Experience Management (MxM) in our pioneering Product Experience Platform, we allow retailers and brand owners to offer the rich, relevant, and emotional product experiences that exceed their customers` expectations. More than 300 customers in 89 countries are using this unique platform. Its flexibility, scalability, and usability give them the power to create and share the product experiences their customers demand — today and tomorrow — on any channel. We are recognized by Forrester Research as a PIM technology leader.